TRPC6 channel blocker as potential therapeutics for pulmonal and renal diseases

The invention comprises diterpene derivatives for the treatment of pulmonary hypertension in conjunction with respiratory disorders, especially asthma and COPD. The pharmacological effect is mediated by selective block of TRPC6, a member of the subfamily of canonical transient receptor potential channels.

Further Information: PDF

GWT-TUD GmbH; FB Sächsische PatentVerwertungsAgentur (SPVA)
Phone: +49 351 25933 120

Contact
Beate-Victoria Ermisch

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

The Sound of the Perfect Coating

Fraunhofer IWS Transfers Laser-based Sound Analysis of Surfaces into Industrial Practice with “LAwave”. Sound waves can reveal surface properties. Parameters such as surface or coating quality of components can be…

Customized silicon chips

…from Saxony for material characterization of printed electronics. How efficient are new materials? Does changing the properties lead to better conductivity? The Fraunhofer Institute for Photonic Microsystems IPMS develops and…

Acetylation: a Time-Keeper of glucocorticoid Sensitivity

Understanding the regulatory mechanism paves the way to enhance the effectiveness of anti-inflammatory therapies and to develop strategies to counteract the negative effects of stress- and age-related cortisol excess. The…

Partners & Sponsors